8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 23, 2026·SEC
Galecto, Inc.(GLTO)Earnings, Financials & Key Ratios
GLTO•NASDAQ
$21.58
Price updated Jun 20, 2026
AboutGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$211M-854.9%
- Net Income-$210M-878.8%
- EPS (Diluted)-3.71+80.0%
- ROE-163.8%-84.0%
GLTO Price & Volume
Galecto, Inc. (GLTO) stock price & volume — 10-year historical chart
Loading chart...
GLTO Growth Metrics
Galecto, Inc. (GLTO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1171.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-24.78%
Return on Capital
10 Years-77.21%
5 Years-89.2%
3 Years-113.69%
Last Year-164.49%
GLTO Recent Earnings
Galecto, Inc. (GLTO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.62-59.9%
$0.39
Rev
—
—
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$3.24-2216.3%
$0.14
Rev
—
—
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$2.36
—
Rev
—
—
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$2.60
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.62vs $0.39-59.9% | — |
| Q2 2026 | Mar 18, 2026 | $3.24vs $0.14-2216.3% | — |
| Q4 2025 | Nov 6, 2025 | $2.36 | — |
| Q3 2025 | Aug 5, 2025 | $2.60 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Galecto, Inc. (GLTO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.58 | $34.47M | -5.82 | — | — | -163.8% | — | |
| $4.23 | $278.57M | -8.81 | — | — | — | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $3.55 | $4.48M | -0.07 | -81.82% | -2530.85% | — | — | |
| $53.63 | $8.21B | 19.36 | 87.32% | 65.95% | 87.36% | — | |
| $9.27 | $485.31M | -2.05 | -92.84% | -260.92% | -49.88% | — |
Compare GLTO vs Peers
Galecto, Inc. (GLTO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GLTO SEC Filings & Documents
Galecto, Inc. (GLTO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GLTO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GLTO Frequently Asked Questions
Galecto, Inc. (GLTO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GLTO profitable?
Galecto, Inc. (GLTO) reported a net loss of $235.1M for fiscal year 2025.
Dividend & Returns
What is GLTO's return on equity?
Galecto, Inc. (GLTO) has a return on equity (ROE) of -163.8%. Negative ROE indicates the company is unprofitable.
What is Galecto, Inc.'s free cash flow?
Galecto, Inc. (GLTO) had negative free cash flow of $24.9M in fiscal year 2025, likely due to heavy capital investments.